3-[[2 inverted exclamation mark -(1H-Tetrazol-5-yl)-[1,1 inverted exclamation mark -biphenyl]-4-yl]methyl]-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one

名称与同义词

• irbesartan
• Avapro
• Aprovel
• Karvea
• 138402-11-6
• Irbesartan BMS
• Sarbevel
• Irbetan
• Irbesartan-d3
• Irbesartan teva
• Irbesartan Krka
• ifirmasta
• Irbesartan Zentiva
• Irbesarran
• Lrbesartan
• Sabervel
• Avalide
• irbesartanum
• Irbesartan Winthrop
• Irbesartan D4
• [3H]irbesartan
• Irbesartan?
• Irbesartan HCl
• Aprovel;
• Irbesartan CRS
• Irbesartan-d7
• Avapro;
• BMS-186295
• Irbesartan free base
• Avapro (TN)
• Irbesartan [USAN:INN]
• SR-47436
• Aprovel (TN)
• Avalide (TN)
• Karvea (TN)
• Irbesartan (Avapro)
• Irbesartan(Avapro)/
• Irbesartan (Standard)
• Irbesartan hydrochloride
• IRBESARTAN 1G
• IRBESARTAN 5G
• Spectrum_001751
• 2,4-Dichloropyrimidine
• Ac-Lys(Z)-OH
• SR 47436
• IRBESARTAN [MI]
• RefChem:57688
• BMS 186295
• DTXSID0023169
• BMS Brand of Irbesartan
• MFCD00864464
• AC1L1GMK
• C25H28N6O
• IRBESARTAN [INN]
• IRBESARTAN [JAN]
• Spectrum2_001675
• Spectrum3_000994
• Spectrum4_001122
• Spectrum5_001288
• CHEMBL1513
• IRBESARTAN [USAN]
• YOSHYTLCDANDAN-UHFFFAOYSA-N
• IRBESARTAN [VANDF]
• D00JAU
• D0F8KG
• UNII-J0E2756Z7N
• IRBESARTAN [MART.]
• SCHEMBL4246
• CHEBI:5959
• DTXCID903169
• IRBESARTAN [USP-RS]
• IRBESARTAN [WHO-DD]
• J0E2756Z7N
• BSPBio_002687
• GTPL589
• KBioGR_001603
• KBioSS_002231
• HSDB 8215
• MLS000759408
• MLS001424099
• BIDD:GT0347
• Irbesartan (JAN/USAN/INN)
• IRBESARTAN [EMA EPAR]
• NSC-758696
• SCHEMBL285754
• SPECTRUM1504259
• SPBio_001889
• GTPL6908
• Irbesartan (JP18/USP/INN)
• Irbesartan - Bio-X trade mark
• Irbesartan [USAN:USP:INN:BAN]
• orb1308006
• Jsp002315
• IRBESARTAN [EP IMPURITY]
• IRBESARTAN [ORANGE BOOK]
• ERK5-3D06
• HY-B0202R
• KBio2_002231
• KBio2_004799
• KBio2_007367
• KBio3_001907
• KS-00000ISW
• 138402-11-6 (free base)
• C09CA04
• CID3749
• COAPROVEL COMPONENT IRBESARTAN
• EBD8758
• IRBESARTAN [EP MONOGRAPH]
• IRBESARTAN [USP IMPURITY]
• Bristol Myers Brand of Irbesartan
• BCPP000202
• GLXC-04552
• HMS1922J05
• HMS2051L08
• HMS2093E16
• HMS2232F23
• HMS3370B06
• HMS3393L08
• HMS3715L04
• HMS5087C17
• IRBESARTAN [USP MONOGRAPH]
• Pharmakon1600-01504259
• SanofiWinthrop Brand of Irbesartan
• AVALIDE COMPONENT IRBESARTAN
• IFIRMACOMBI COMPONENT IRBESARTAN
• BCP02004
• CID:3749
• HY-B0202
• MSK10063
• SR47436
• ZINC3872931
• Tox21_111433
• ABP000523
• AC-537
• BDBM50042235
• C25-H28-N6-O
• CCG-39091
• MFCD18384966
• NCGC00095122-01
• NP3710
• NSC758696
• STK645362
• AKOS005576396
• AKOS015895353
• Irbesartan, >=98% (HPLC), powder
• Tox21_111433_1
• AB07472
• AM90289
• BCP9000792
• CCG-101012
• CS-2140
• DB01029
• EBC-145051
• FI24648
• KS-1151
• NC00262
• NSC 758696
• 3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
• NCGC00095122-02
• NCGC00095122-03
• NCGC00095122-04
• NCGC00095122-05
• NCGC00095122-14
• 4CA-0654
• AK-57149
• AN-15743
• BC207567
• BI164582
• BR-57149
• CPD000466306
• H931
• LS-60064
• SAM001246548
• SC-08814
• SMR000466306
• SY051244
• SBI-0206769.P001
• SID:376229507
• AB0013366
• AB1009632
• J549.417F
• TL8000875
• 2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
• A-779
• A5970
• CAS-138402-11-6
• FT-0601598
• FT-0670413
• I0859
• NS00000387
• S1507
• SR-47436;BMS-186295
• ST24028252
• BMS-186295, SR-47436
• A10477
• C07469
• D00523
• J10394
• S-1797
• 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
• 54246-EP2270011A1
• 54246-EP2295406A1
• 54246-EP2295422A2
• 54246-EP2298772A1
• 54246-EP2298776A1
• 54246-EP2298779A1
• 54246-EP2301923A1
• 54246-EP2301931A1
• 54246-EP2305219A1
• 54246-EP2308562A2
• 54246-EP2308839A1
• AB00639954-06
• AB00639954_07
• AB00639954_08
• 2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(4.4)non-1-en-4-one
• 2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
• 402I116
• A807387
• C081309
• EN300-37158602
• L000319
• Q947266
• SR-05000001997
• 1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-
• I06-0690
• IBERSARTAN/HYDROCHLOROTHIAZIDE COMPONENT IBERSARTAN
• SR-05000001997-1
• (-)-Styrene glycol; (R)-(-)-Phenylethylene glycol
• 2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one
• 8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one
• BRD-K60038276-001-02-5
• BRD-K60038276-001-03-3
• BRD-K60038276-001-08-2
• BRD-K60038276-001-09-0
• IBERSARTAN/HYDROCHLOROTHIAZIDE TEVA COMPONENT IBERSARTAN
• 1185120-76-6
• BMS-186295, SR-47436,Aprovel, Karvea, Irbesartan
• D000077405
• IBERSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA COMPONENT IBERSARTAN
• 2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one
• Irbesartan, European Pharmacopoeia (EP) Reference Standard
• 2-BUTYL-3-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1,3-DIAZASPIRO[4.4]NON-1-EN-4-ONE
• 2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
• 3-BUTYL-2-[[4-[2-(2H-TETRAZOL-5-YL)PHENYL]PHENYL]METHYL]-2,4-DIAZASPIRO[4.4]NON-3-EN-1-ONE
• Irbesartan, United States Pharmacopeia (USP) Reference Standard
• 2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[4.4]non-1-en-4-one
• 3-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
• Irbesartan, Pharmaceutical Secondary Standard; Certified Reference Material
• 2-butyl-3-[ p -( o -1 H -tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one
• 2-butyl-3-[ p-(o-1 H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one
• 1,3-Diazaspiro[4.4]non-1-en-4-one,2-butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
• 1-[[2 -(2H-Tetrazole-5-yl)-1,1 -biphenyl-4-yl]methyl]-2-butylspiro[2-imidazoline-4,1 -cyclopentane]-5-one
• 1-[4-[2-(1H-Tetrazole-5-yl)phenyl]benzyl]-2-butylspiro[1H-imidazole-4(5H),1 -cyclopentane]-5-one
• 1216883-23-6
• 1242281-36-2
• 1329496-43-6
• 2-(~2~H_9_)Butyl-3-{[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
• 2-(n-butyl)-3-[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
• 2-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4.4)non-1-en-4-one
• 2-butyl-3-((4-(2-(2H-1,2,3,4-tetrazol-5-yl)phenyl)phenyl)methyl)-1,3-diazaspiro(4.4)non-1-en-4-one
• 2-butyl-3-((4-(2-(2H-tetrazol-5-yl)phenyl)phenyl)methyl)-1,3-diazaspiro(4.4)non-1-en-4-one
• 2-butyl-3-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one
• 2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one
• 2-Butyl-3-[[2 -(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
• 2-BUTYL-3-[[2'-(1H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1,3-DIAZASPIRO[4.4]NON-1-EN-4-ONE
• 2-Butyl-3-[2 -(1H-tetrazole-5-yl)-4-biphenylylmethyl]-1,3-diazaspiro[4.4]nona-1-ene-4-one
• 2-Butyl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[4.4]non-1-en-4-one
• 2-butyl-3-{[2''-(1H-tetrazol-5-yl)[1,1''-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
• 2-butyl-3-{[2''-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
• 2-butyl-3-{[2'-(1H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
• 2-butyl-3-{[2'-(2H-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
• 2-n-butyl-3-<<2'-(1H-tetrazol-5-yl)biphenyl-4-yl>methyl>-1,3-diazaspiro<4.4>non-1-en-4-one;
• 3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)-methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
• 3-((2'-(1H-Tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one =98.0% (by HPLC, titration analysis)
• 3-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
• 3-((2`-(1H-Tetrazol-5-yl)-[1,1`-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
• 3-[[2 inverted exclamation mark -(1H-Tetrazol-5-yl)-[1,1 inverted exclamation mark -biphenyl]-4-yl]methyl]-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
• 604-078-2
• Irbesartan, 99%, a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist - 1G 1g
• Irbesartan; 2-Butyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one